Instil Bio, Inc.

TIL Healthcare Biotechnology

In the quarter to June 2026, EPS grew 80.6%, free cash flow grew 68.6% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

5.91 0.22 −3.59%
Market cap
$41.6M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
14.03 15.75 15.81 21.16
Current Ratio
34.45 39.53 39.87 21.67
Net Debt/EBITDA
(0.31) (0.89) (1.47) (2.86)
Debt/Assets
39.96% 41.67% 42.41% 43.09%
Debt/Equity
0.70 0.74 0.77 0.79
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.78 0.86 0.32 1.08
Capex/Depreciation
0.00 0.00 0.00 0.00
Interest Coverage
(9.50) (6.10) (4.52) (3.53)
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(1.56) (1.06) (0.20) (0.68)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(1.56) (1.06) (0.20) (0.68)
Cash per Share
11.83 11.44 11.01 10.31
Shareholders Equity per Share
17.82 17.08 16.32 15.83
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
17.82 17.08 16.32 15.83
Free Cash Flow
(10.56) (7.08) (1.34) (4.64)
Working Capital
190.57 186.59 183.58 68.30
Net Current Asset Value
104.92 101.77 98.57 (18.73)
Other line items
Average Payables
1.06 0.72 0.54 0.66
Average Assets
242.17 233.55 218.94 214.35
Average Common Equity
148.38 141.65 127.81 119.53

Fold the line items

Columns are period end dates